Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders

Autor: Arturo Arellano, María Verónica Rey, Bezner Paz, Mauricio Rovelo, José Calderón, Byron Recinos, Santiago Perez Lloret, Luis Molina, Fanny Elizabeth Rodriguez Elias
Rok vydání: 2018
Předmět:
Adult
Male
medicine.medical_specialty
Bipolar Disorder
CIENCIAS MÉDICAS Y DE LA SALUD
Movement disorders
medicine.medical_treatment
BIPOLAR DEPRESSIVE DISORDER
Medicina Clínica
DRUG-INDUCED MOVEMENT DISORDERS
03 medical and health sciences
Sex Factors
0302 clinical medicine
Internal medicine
medicine
Humans
Pharmacology (medical)
Antipsychotic
Prospective cohort study
Depression (differential diagnoses)
MAJOR DEPRESSIVE DISORDER
Pharmacology
Depressive Disorder
Movement Disorders
business.industry
SCHIZOPRHENIA
Neurología Clínica
Odds ratio
Middle Aged
medicine.disease
Confidence interval
030227 psychiatry
Schizophrenia
Case-Control Studies
ANTIPSYCHOTIC DRUGS
PHARMACOVIGILANCE
Multivariate Analysis
Major depressive disorder
Female
Neurology (clinical)
medicine.symptom
business
030217 neurology & neurosurgery
Antipsychotic Agents
Zdroj: Clinical Neuropharmacology. 41:177-180
ISSN: 1537-162X
0362-5664
DOI: 10.1097/wnf.0000000000000300
Popis: Objectives The aims of the study were to explore the frequency of movement disorders (MDs) in depressive patients exposed to antipsychotic drugs (APDs) and to compare it with nonexposed depressive patients and APDs-treated schizophrenic patients. Methods Four hundred fifty-two depressive patients not exposed to APDs (group A), 156 depressives exposed to APDs (group B), and 75 patients with schizophrenia on APDs (group C) were recruited. Presence of MDs was explored by the Simpson-Angus and UKU scales (Registration: NCT02409823). Results Movement disorders were observed in 5%, 9%, and 13% of patients in groups A to C, respectively (P < 0.001, χ2 for linear trend). A logistic multivariate analysis revealed that male sex (odds ratio = 2.26, 95% confidence interval = 1.13–4.49, P < 0.01), exposure to first-generation (vs second-generation) APDs (odds ratio = 5.71, 95% confidence interval = 2.08–15.66, P < 0.01), and exposure to lithium (odds ratio = 3.99, 95% confidence interval = 1.74–9.14, P < 0.01) were independently and significantly associated with MDs. Conclusions Male sex, use first-generation APDs, and exposure to lithium were associated with MDs in depression. Therefore, caution is advised with the use of these drugs in depressive patients. Prospective studies are needed to confirm these results. Fil: Rey, María Verónica. Etymos Consulting Group; Argentina Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro; Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras Fil: Rodriguez Elias, Fanny Elizabeth. Colonia Médica; El Salvador Fil: Calderón, José. Clínica de la Conducta; Panamá Fil: Arellano, Arturo. Drugtech, Corporación Farmacéutica Recalcine; Costa Rica Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
Databáze: OpenAIRE
Externí odkaz: